Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 911-915-8 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Objective of study:
- absorption
- distribution
- excretion
- Qualifier:
- according to guideline
- Guideline:
- other: Japanese Guidelines for Non-clinical Studies of Drugs Manual 1995; Guidelines for Toxicity Studies of Drugs. Japanese Ministry of Health and Welfare.
- GLP compliance:
- yes (incl. QA statement)
- Radiolabelling:
- yes
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Deutschland GmbH, Sandhofer Weg 7, D-97633 Sulzfeld
- Age at study initiation: 6-12 weeks
- Weight at study initiation: 150-259 g
- Housing: animals were kept singly in MAKROLON cages (type III) during adaptation period
- Individual metabolism cages: yes, during excretion study
- Diet (ad libitum): Altromm 1321 (ALTROMIN GmbH, D-32791 Lage/Lippe
- Water (ad libitum)
- Acclimation period: 1 week
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22°C ± 3°C
- Humidity (%): 60% ± 20%
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- other: oral or intravenous
- Vehicle:
- other: aqua ad iniectabilia
- Details on exposure:
- Dose level and formulation:
Each rat received approx. 0.8 m g Hydroxyethyl-14C-Oleaflur or approx. 0.2 mg Oleyl-14C-Oleaflur, corresponding to a nominal radioactive dose of approx. 876 kBq (approx. 24uCi) per animal. Each animal received a dosage of approx. 3.5 MBq/kg bw .
Depending on the specific activity of the labelled substances, unlabelled test material was added until a specific total dosage of 20 mg/kg bw Oleaflur (labelled + unlabelled) was reached.
Oral formulation: the test articles were dissolved in aqua ad iniectabilia. A constant volume (10 mL) of dose formulation per kg body weight was administered (dose 20 mg/kg bw).
Intravenous formulation: the test articles were dissolved in aqua ad iniectabilia containing 33 mg/mL mannitol and 0.5 mg/mL sodium EDTA. A constant volume of dose formulation per kg body weight was administered. (dose: 20 mg/kg bw , application volume: 4.0 mL/kg bw) - Duration and frequency of treatment / exposure:
- - 1 application day and up to 96 hours post administration sampling
- Dose / conc.:
- 20 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- - 6 per sex per dose per route of administration per compound
- Control animals:
- no
- Preliminary studies:
- - no data
- Details on absorption:
- Within 96 h of receiving a single oral administration of Hydroxyethyl-14C-Oleaflur, means of 90.74 % and 93.95 % of the administered radioactivity were recovered in urine (means 47.20 % and 51.63 %), faeces (means 27,65 % and 23.54 %), expired air (means 2.94 % and 2.01 %), carcass and organs (means 9.53 % and 10.86 %) and rinse water (means 3.41 % and 5.90 %) of male and female animals, respectively.
Within 96 h of receiving a single oral administration of Oleyl-14C-Oleaflur, (means of 95.78 % and 96.92 % of the administered radioactivity were recovered in urine (means 30.41 % and 33.11 %), faeces (means 30.83 % and 34.69 %), expired air (means 18.83 % and 18.49 %), carcass and organs (means - 13.16 % and 7.98 %) and rinse water (means 2.55 % and 2.66 %) of male and female animals, respectively.
Within 96 h of receiving a single intravenous administration of Hydroxyethyl-14C-Oleaflur means of 95.60 % and 91.54 % of the administered radioactivity were recovered in urine (means 49.43 % and 49.90 %), faeces (means 25.83 % and 23.86 %), expired air (means 3.94 % and 2.96 %), carcass and organs (means 13.34 % and 11.40 %) and rinse water (means 3.06 % and 3.42 %) of male and female animals, respectively.
Within 96 h of receiving a single intravenous administration of Oleyl-14C-Oleaflur means of 93.34 % and 90.67 % of the administered radioactivity were recovered in urine (means 39.14 % and 39.19 %), faeces (means 28.14 % and 21.62 %, expired air (means 14.83 % and 11.56 %), carcass and organs (means 8.17 % and 15.04 %, and rinse water (means 3.06 % and 3.27 %, of male and female animals, respectively. - Details on distribution in tissues:
- A widespread and generally uniform distribution of radioactivity in the tissue was observed at 96 h after oral administration for both Oleaflur compounds. The highest concentrations of radioactivity were observed in the kidneys for Hydroxyethyl-14C-Oleaflur (males 16.35 ug-eq/g, females 30.42 ug-eq/g) and in the liver (males 12.58 ug-eq/g, females 18.64 ug-eq/g). Oleyl-14C-Oleaflur related radioactivity was counted mainly in the adipose tissue (males 31.68 ug-eq/g, females 16.99 ug-eq/g) and in the adrenals (males 8.86 ug-eq/g, females 5.94 ug-eq/g).
A widespread and generally uniform distribution of radioactivity in the tissue was observed at 96 h after intravenous administration for both Oleaflur compounds. The highest concentrations of radioactivity were observed in the kidneys for Hydroxyethyl-14C-Oleaflur (males 9.73 ug-eq/g, females 15.91 ug-eq/g) and in the liver (males 8.13 ug-eq/g, females 10.54 ug-eq/g). Oleyl-14C-Oleaflur related radioactivity was counted mainly in the adipose tissue (males 3.70 ug-eq/g, females 4.73 ug-eq/g) and in the pituitary (males 4.33 ug-eq/g, females 3.48 ug-eq/g). - Details on excretion:
- The most important route of elimination was the urine with between 30 to 50 %: slightly more radioactivity was excreted with the urine for the Hydroxy14C-Oleaflur than for the Oleyl-14C-Oleaflur. The reverse was observed for expired air: approximately 12 to 19 % was excreted with the air for Oleyl-14C-Oleaflur and only 2 to 4 % for Hydroxyethyl-14C-Oleaflur.
- Metabolites identified:
- not measured
- Executive summary:
No study with Olaflur is available. However, the bioavailability of Olaflur can reliably be predicted, from data obtained with a chemically very similar compound (Oleaflur).
In an absorption, distribution and excretion study (LPT, 2003) two radiolabelled Oleaflur compounds, Hydroxyethyl-14C-Oleaflur and Oleyl-14C-Oleaflur, have been studied for 96 hours in Sprague-Dawley rats given a single oral or intravenous nominal dose level of 20 mg/kg bw.
The radiolabelled compounds were completely absorbed (> 90 %) following oral administration. Routes of excretion were fairly similar for both labelled compounds with a predominance of urinary excretion. There was no difference in the distribution of radioactivity in the tissues for both compounds or for the two routes of administration. Oral or intravenous administration resulted in no changes in the routes of excretion for both compounds.
No sex difference was observed in the plasma concentrations, excretion patterns and tissue distribution, and no indications were found that Oleaflur might accumulate in the body (t 1/2 i.v. = approx. 46 h for Hydroxyethyl-14C-Oleaflur and approx. 32 h for Oleyl-14C-Oleaflur; after absorption or intravenous administration, approximately 60 % of the dose was excreted within the first 24 hours).
Reference
Description of key information
No
study with Olaflur is available. However, the bioavailability of
Olaflur can reliably be predicted from data obtained with a chemically
very similar compound (Oleaflur).
In an absorption, distribution and excretion study (LPT, 2003) two
radiolabelled Oleaflur compounds, Hydroxyethyl-14C-Oleaflur and
Oleyl-14C-Oleaflur, have been studied for 96 hours in Sprague-Dawley
rats given a single oral or intravenous nominal dose level of 20 mg/kg
bw.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
In an absorption, distribution and excretion study (LPT, 2003) two radiolabelled Oleaflur compounds, Hydroxyethyl-14C-Oleaflur and Oleyl-14C-Oleaflur, have been studied for 96 hours in Sprague-Dawley rats given a single oral or intravenous nominal dose level of 20 mg/kg bw.
The radiolabelled compounds were completely absorbed (> 90 %) following oral administration. Routes of excretion were fairly similar for both labelled compounds with a predominance of urinary excretion. There was no difference in the distribution of radioactivity in the tissues for both compounds or for the two routes of administration. Oral or intravenous administration resulted in no changes in the routes of excretion for both compounds.
No sex difference was observed in the plasma concentrations, excretion patterns and tissue distribution, and no indications were found that Oleaflur might accumulate in the body (t 1/2 i.v. = approx. 46 h for Hydroxyethyl-14C-Oleaflur and approx. 32 h for Oleyl-14C-Oleaflur; after absorption or intravenous administration, approximately 60 % of the dose was excreted within the first 24 hours).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.